Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study1,2

Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat

(2010) E. Sebokova et al.   DIABETES OBESITY & METABOLISM

Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability andin VivoPotency

(2010) Elena Sebokova et al.   ENDOCRINOLOGY

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

(2009) M. A. Nauck et al.   DIABETES CARE

Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes

(2009) C. Kapitza et al.   DIABETIC MEDICINE

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE